Boesman-Finkelstein M, Peterson J W, Thai L S, Finkelstein R A
Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia 65212, USA.
Infect Immun. 1996 Jan;64(1):346-8. doi: 10.1128/iai.64.1.346-348.1996.
The gene encoding a nontoxic analog, CT-2*, of cholera enterotoxin (CT) with attenuating codon substitutions in the A subunit was introduced into the attenuated Vibrio cholerae classical biotype mutant candidate vaccine strain CVD103, which produces the B subunit (but not the A subunit) of CT-1. The recombinant strain produces a chimeric nontoxic analog holotoxin containing both CT-B-1 and CT-B-2 subunits. This offers potential advantages over CVD103 in the induction of immunity against E1 Tor biotype and V. cholerae O139 strains which produce CT-B-2. The recombinant protein may also be useful in polysaccharide-protein conjugate vaccines against both O1 and O139 serovars of V. cholerae.
编码霍乱肠毒素（CT）无毒类似物CT-2*的基因，其A亚基中有减毒密码子替换，被导入减毒的霍乱弧菌古典生物型突变候选疫苗株CVD103中，该菌株产生CT-1的B亚基（但不产生A亚基）。重组菌株产生一种嵌合无毒类似全毒素，包含CT-B-1和CT-B-2亚基。这在诱导针对产生CT-B-2的埃尔托生物型和霍乱弧菌O139菌株的免疫方面，相对于CVD103具有潜在优势。该重组蛋白也可能用于针对霍乱弧菌O1和O139血清型的多糖-蛋白结合疫苗。
